AMSTERDAM and VALHALLA, N.Y., Nov. 11, 2016 /PRNewswire/ -- Royal Philips (NYSE: PHG; AEX: PHIA) and the Westchester Medical Center Health Network (WMCHealth), the leading provider of advanced medical care in New York's Hudson Valley, today announced the launch of WMCHealth's new precision medicine initiative for personalized cancer treatment, which will use Philips' IntelliSpace Genomics solution to integrate large-scale genomic analysis with extensive patient clinical data.
WMCHealth leverages Philips IntelliSpace Genomics to combine the output from next-generation sequencing (NGS) with clinical data and advanced information sharing, to provide a comprehensive patient view for precision-tailored treatment. With base operations at its flagship Westchester Medical Center, the WMCHealth precision medicine initiative will be available to all hospitals in the WMCHealth Network, as well as other facilities in the Hudson Valley and beyond.
Philips' IntelliSpace Genomics is a configurable, scalable and secure health informatics solution across hospitals for delivering real-time, actionable diagnostic information to physicians and specialists for therapy planning at the point of care. Philips IntelliSpace Genomics' collaborative solution enables physicians to answer key clinical questions by leveraging the best clinical expertise and algorithmic power in integrated workflows. It seamlessly brings data from multiple sources – including raw sequencing data, up-to-date in silico genomic databases, clinical data and knowledge databases, longitudinal patient records, medical images and pathology data, among others.
"Our team at WMCHealth sees and treats the most complex cancer cases. Our new precision medicine platform for oncology is designed to leverage all available sources of critical information to help make the most informed decisions about each patient's care," said John Fallon, MD, PhD, Director, Department of Clinical Pathology, Westchester Medical Center, and Chairman of Pathology, New York Medical College. "WMCHealth's new cancer diagnostic program gives us greater capabilities to test and validate clinical planning, through the fusion of highly specific and individualized patient information with massive and growing genomic knowledge of cancer."
Dr. Fallon added, "The Philips IntelliSpace Genomics solution is a foundation for designing possible therapy plans in a digital framework, such as how to match a tumor's genotype with a potential drug for the best outcome, for example, or matching patients with clinical trials. This is a powerful tool to help improve outcomes through precision medicine."
The genomics project is part of a larger investment by WMCHealth into groundbreaking diagnostic and treatment capabilities, including WMCHealth's new Cellular & Tissue Engineering Laboratory (CTEL), home to state-of-the-art technology that facilitates cellular therapy under investigational new drug applications in support of treatments for a variety of hematological and oncological disorders and diseases.
The IntelliSpace Genomics solution can be configured to define new workflows, create new pipelines, or integrate new sources of data as required, and can be used for collaborative clinical analysis and sharing across multiple hospitals and their affiliates, either on-site or in the cloud.
The Philips' IntelliSpace Genomics solution is built on Philips HealthSuite, a cloud-enabled connected health ecosystem of devices, apps and digital tools that work seamlessly together to enable personalized integrated health and continuous care.
"As the number of targeted cancer drugs and clinical trials continue to expand, it is critical to give clinicians insight into genetic mutations driving a particular patient's cancer, along with the complete patient context of diagnostic tests and medical history to enable a precise focus on personalized treatment," said Louis Culot, General Manager of Philips Genomics.
Culot noted, "The new WMCHealth platform leverages Philips IntelliSpace Genomics' informatics capabilities to help achieve this, as well as to provide physicians with a networked solution that offers a single integrated interface for collaboration between doctors and institutions."
For further information, please contact:
Westchester Medical Center Health Network
Tel.: +1 914-493-6532
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips' health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 70,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
About Westchester Medical Center Health Network
The Westchester Medical Center Health Network (WMCHealth) is a 1,700-bed healthcare system headquartered in Valhalla, New York, with 10 hospitals on eight campuses spanning 6,200 square miles of the Hudson Valley. WMCHealth employs more than 12,000 people and has nearly 3,000 attending physicians. From Level 1, Level 2 and Pediatric Trauma Centers, the region's only acute care children's hospital, an academic medical center, several community hospitals, dozens of specialized institutes and centers, skilled nursing, assisted living facilities, homecare services and one of the largest mental health systems in New York State, today WMCHealth is the pre-eminent provider of integrated healthcare in the Hudson Valley. For more information about WMCHealth, visit WMCHealth.org.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/westchester-medical-center-health-network-launches-new-precision-medicine-initiative-to-personalize-cancer-care-powered-by-philips-intellispace-genomics-300361096.html
SOURCE Royal Philips